Post Liver Transplant Clinical Trial
Official title:
A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of GS-7977 and Ribavirin for 24 Weeks in Subjects With Recurrent Chronic HCV Post Liver Transplant
This is an open-label, single-arm study of sofosbuvir (GS-7977) and ribavirin (RBV) in adults who have had a liver transplant which has become re-infected with hepatitis C. The treatment period is 24 weeks with up to 48 weeks of follow up. The total time in this study will last up to 72 weeks not including the screening visit.
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05063071 -
Tenofovir Alafenamide for HBV Prophylaxis in Post Orthotopic Liver Transplant
|
Phase 4 | |
Active, not recruiting |
NCT03386305 -
Evaluate the Clinical Benefits of EnvarsusXR in Post Liver Transplant
|
Phase 2/Phase 3 | |
Recruiting |
NCT06304467 -
CM for Patients With ALD After Liver Transplant
|
N/A |